TQB6411 not checked
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQB6411 Injection is an antibody-drug conjugate (ADC) targeting Epidermal Growth Factor Receptor (EGFR)/c-Met.”In the company’s words, NCT07367516 on ClinicalTrials.gov
- Main trialPhase 1/2
- “The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.”In the company’s words, NCT07367516 on ClinicalTrials.gov
Other drugs for Esophageal Cancer
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- DurvalumabAstraZeneca · Phase 3
- RilvegostomigAstraZeneca · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
Coming up3
- Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Feb 2027 | Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | |
| Phase 1/2Recruiting | Dec 2028 | A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection | |
| Phase 1Recruiting | Dec 2027 | A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026